The U.S. Food and Drug Administration has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD).
This article was originally published on MedicalXpress.com
FDA approves Opzelura for atopic dermatitis in children
You may also be interested in:
The Latest
Microneedling Services in Edmonton: Benefits, Treatment Cost, and How It Works
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
The Latest
Twelve Foot Massage Techniques To Try Today
In this article, we will introduce you to 12 incredibly effective foot massage techniques that will leave you feeling rejuvenated and relaxed. Foot massages aren’t just a luxury; they provide numerous health benefits, such as […]
The Latest
Setting Boundaries: Nurturing a Healthy Partnership
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
Read More:
-
Results from a randomized clinical trial published in Pediatrics show that pediatricians who received targeted educational and clinical decision-support tools were significantly more likely to [...]
-
The U.S. Food and Drug Administration has approved Johnson & Johnson’s Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children [...]
-
Family affluence shields children from the risks of obesity and unhealthy eating habits, even when they’re surrounded by unhealthy food options, according to a study [...]
